Steriwave shown to reduce resistant bacteria
18 October 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Steriwave shown to reduce resistant bacteria by >99.9%
· New research presented by Ondine shows that Steriwave photodisinfection reduces antibiotic-resistant bacteria by more than 99.9% without generating resistance.
· The research suggests that photodisinfection is a viable alternative to antibiotics.
Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) is today presenting new research showing that Steriwave® photodisinfection reduced antibiotic-resistant bacteria by more than 99.9%. The in vitro study, which is being presented today at the IP2023 Annual conference taking place in Liverpool 17-19 October 2023, indicates that photodisinfection is likely to play an important role in strategies for combatting antimicrobial resistance (AMR).
The controlled study evaluated the efficacy of Ondine's Steriwave® photodisinfection against Gram-negative and Gram-positive multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria with novel antibiotic resistance factors. All of the bacterial strains used in the study exhibited resistance against some of the most commonly prescribed antibiotic classes, including penicillin, tetracyclines, quinolones and carbapenems.
The results of the study showed that treatment with photodisinfection resulted in >99.9% reduction of viable bacteria compared to the control, regardless of the antibiotic susceptibility of the bacteria. The authors concluded that photodisinfection is likely an important adjunct to AMR strategies in the future and that further clinical studies are warranted.
Antimicrobial resistance (AMR) remains a major public health concern, causing 33,000 deaths in Europe annually[1] which is projected to rise to over 10 million globally by 2050.[2] There are widespread multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections across the world which are mainly caused by Gram-negative bacteria including Enterobacteriaceae and P. aeruginosa AMR bacteria[3],[4] and Gram-positive bacteria such as Staphylococcus spp.[5] Steriwave has been found to be highly effective against all these pathogens.
Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation.
Carolyn Cross, CEO of Ondine, commented:
"We continue to demonstrate, both clinically in hospitals across Canada and in the lab, that photodisinfection can provide a real alternative to topical antimicrobials which are no longer effective against an increasing number of pathogens. The evidence continues to show that photodisinfection destroys all types of pathogens including viruses, bacteria and fungi even those in biofilm, and we believe this technology can save millions of lives. The results of this study are particularly welcome as we prepare for our US Phase 3 trial in partnership with HCA Healthcare who are providing invaluable guidance and support."
The poster presentation, "Antimicrobial Photodynamic Therapy Against Extensively Drug-Resistant (XDR) Gram Negative Isolates With Novel Antibiotic Resistance Factors", is being presented at IP2023 between 1:10pm and 2:40pm (BST) on 18 October 2023. The full poster is available to download here.
|
Ondine Biomedical Inc. |
|
|
Carolyn Cross, CEO |
+001 (604) 665 0555 |
|
|
|
|
Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
|
Aubrey Powell, Asha Chotai, Sam Butcher |
+44 (0)20 7496 3000 |
|
|
|
|
RBC Capital Markets (Joint Broker) |
|
|
Rupert Walford, Kathryn Deegan |
+44 (0)20 7653 4000 |
|
|
|
|
Vane Percy & Roberts (Media Contact) |
|
|
Simon Vane Percy, Amanda Bernard |
+44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
About photodisinfection
Ondine's photodisinfection is a patented technology using a proprietary photosensitizer (non-antibiotic, light-activated solution) to destroy pathogens. When illuminated with a specific wavelength of light, the photosensitizer is activated, causing an oxidative burst that is lethal to all types of pathogens.
Ondine's nasal photodisinfection system has a CE mark and is approved in Canada and several other countries under the name Steriwave™. It has been used in Canada for over ten years, with no serious adverse events reported. In the US, it is currently undergoing clinical trials for regulatory approval.
[1] WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 - 2020 data. Copenhagen: WHO Regional Office for Europe; 2022.
[2] "O'Neill Review into Antibiotic Resistance" https://researchbriefings.files.parliament.uk/documents/CDP-2017-0074/CDP-2017-0074.pdf
[3] Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66. doi:10.1016/S1473-3099(18)30605-4
[4] Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother. 2020;75(2):271-282. doi:10.1093/jac/dkz401
[5]UK Health Security Agency. MRSA, MSSA, Gram-negative bacteraemia and CDI: 30-day all-cause fatality, London: UK Health Security Agency, March 2023.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund